HD21study elderly cohort for Adcetris® in the BrECADD regimen

The HD21 phase 2 study is a prospective, international, multicenter, single-arm supplemental cohort within the HD21-study for patients involving 85 patients aged 61-75 years with newly diagnosed, advanced-stage, cHL. The study assessed the efficacy and safety in elderly patients. [1]


Key results:

  • BrECADD achieved complete remission in 82% of patients with newly diagnosed, adavancedstage cHL (95% CI: 72–90). [1]
  • For the first time a 2-year PFS was achieved in patients aged over 60 years with an estimated PFS after 24 months of 91.5% (95% CI: 84.8–98.2). [1]
  • The overall survival rate in the 2-year follow-up was 90.8% (95% CI: 83.7–98.0) with BrECADD. [1]
  • 87% of patients completed the planned number of treatment cycles due to individual dose adjustments with the majority of patients requiring only one dose reduction in the first four cycles. [1]
  • Normalized quality of life after treatment based on the global health status. [1]
  • Short treatment duration of only 12 weeks and low anthracycline exposure with only 4 cycles of BrECADD in the majority of patients (60%). [1]
     

BrECADD: brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone; cHL: classical Hodgkin lymphoma


Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.


Adcetris® Information for healthcare professionals, www.swissmedicinfo-pro.ch

C-APROM/CH/ADCE/0097 11/2025

Further information

References

  • 1. Ferdinandus J, et al. Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. J Clin Oncol 2025;43(27):2974–2985.